Stock listing

Frankfurt:2VF0 Hemostemix Inc Aktie

German listing (Frankfurt) of Hemostemix Inc · home listing TSXV:HEM

Follow Hemostemix Inc into a list and get an email when it puts out news.

Share price · FWB:2VF0

€0.012 EUR -0.003 (-17.2%)

Close on Nov 20, 2026

Past year -57.6% · daily closes, Nov 20, 2025 – Nov 17, 2026, adjusted for splits
Day range
€0.012 – €0.012 EURNov 20, 2026
Market cap
€2.54M EURAt the close on Nov 20, 2026 · price × 211.4M shares outstanding
52-week range
€0.012 – €0.044 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€0 EURMedian day 0 shares · 63 days with no trades · last 3 months, Aug 20, 2026 – Nov 17, 2026
Hemostemix Inc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TSXV:HEM · Home$0.035 CAD0.000 (0.0%)1,000$0.035$0.035$0.035$0.035Close on Nov 20, 2026
OTC:HMTXF$0.027 USD+0.003 (+11.7%)17,140$0.027$0.027$0.027$0.024Close on Nov 17, 2026
Frankfurt:2VF0€0.012 EUR-0.003 (-17.2%)—€0.012€0.012€0.012€0.015Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 17, 2026 · FWB:2VF0 · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.014-0.007-33.3%€0.014€0.014€0.0140
€0.021+0.001+5.0%€0.021€0.021€0.0210
€0.0200.0000.0%€0.020€0.020€0.0200
€0.0200.0000.0%€0.020€0.020€0.0200
€0.0200.0000.0%€0.020€0.020€0.0200
€0.0200.0000.0%€0.020€0.020€0.0200
€0.020-0.003-13.0%€0.020€0.020€0.0200
€0.0230.0000.0%€0.023€0.023€0.0230
€0.023+0.002+9.5%€0.023€0.023€0.0230
€0.021+0.001+5.0%€0.021€0.021€0.0210
€0.020-0.005-20.0%€0.020€0.020€0.0200
€0.025-0.002-7.4%€0.025€0.025€0.0250
€0.0270.0000.0%€0.025€0.027€0.0240
€0.0270.0000.0%€0.024€0.027€0.0240
€0.0270.0000.0%€0.022€0.027€0.0220
€0.027-0.003-10.0%€0.023€0.027€0.0220
€0.030+0.007+30.4%€0.023€0.030€0.0230
€0.023-0.002-8.0%€0.023€0.023€0.0230
€0.025+0.003+13.6%€0.025€0.025€0.0250
€0.0220.0000.0%€0.022€0.022€0.0220
€0.022-0.003-12.0%€0.022€0.022€0.0220
€0.025+0.001+4.2%€0.025€0.025€0.0250
€0.0240.0000.0%€0.024€0.024€0.0240
€0.0240.0000.0%€0.024€0.024€0.0240
€0.024-0.006-20.0%€0.024€0.024€0.0240
€0.0300.0000.0%€0.030€0.030€0.0300
€0.0300.0000.0%€0.030€0.030€0.0300
€0.030+0.004+15.4%€0.030€0.030€0.0300
€0.0260.0000.0%€0.026€0.026€0.0260
€0.0260.0000.0%€0.026€0.026€0.0260
€0.026+0.002+8.3%€0.026€0.026€0.0260
€0.0240.0000.0%€0.024€0.024€0.0240
€0.0240.0000.0%€0.024€0.024€0.0240
€0.0240.0000.0%€0.024€0.024€0.0240
€0.0240.0000.0%€0.024€0.024€0.0240
€0.024+0.002+9.1%€0.024€0.024€0.0240
€0.022-0.004-15.4%€0.022€0.022€0.0220
€0.0260.0000.0%€0.026€0.026€0.0260
€0.026-0.002-7.1%€0.026€0.026€0.0260
€0.0280.0000.0%€0.028€0.028€0.0280
€0.0280.0000.0%€0.028€0.028€0.0280
€0.028-0.002-6.7%€0.028€0.028€0.0280
€0.030+0.002+7.1%€0.030€0.030€0.0300
€0.0280.0000.0%€0.028€0.028€0.0280
€0.028-0.002-6.7%€0.028€0.028€0.0280
€0.030+0.002+7.1%€0.030€0.030€0.0300
€0.028-0.002-6.7%€0.028€0.028€0.0280
€0.0300.0000.0%€0.030€0.030€0.0300
€0.0300.0000.0%€0.030€0.030€0.0300
€0.0300.0000.0%€0.030€0.030€0.0300
€0.0300.0000.0%€0.030€0.030€0.0300
€0.0300.0000.0%€0.030€0.030€0.0300
€0.030+0.002+7.1%€0.030€0.030€0.0301,000
€0.0280.0000.0%€0.028€0.028€0.0280
€0.028-0.002-6.7%€0.028€0.028€0.0280
€0.030-0.002-6.3%€0.030€0.030€0.0300
€0.032+0.001+3.2%€0.032€0.032€0.0320
€0.031+0.001+3.3%€0.031€0.031€0.0310
€0.030+0.003+11.1%€0.030€0.030€0.0300
€0.027-0.002-6.9%€0.027€0.027€0.0270
€0.0290.0000.0%€0.029€0.029€0.0290
€0.029-0.003-9.4%€0.029€0.029€0.0290
€0.0320.0000.0%€0.032€0.032€0.0320
€0.032+0.002+6.7%€0.032€0.032€0.0320
Ticker
Frankfurt:2VF0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Hemostemix Inc news

Hemostemix Inc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
32 in the last 12 months · 217 in all · newest Nov 20, 2026 · oldest 2013
Decks
14 decks · latest Nov 4, 2026

Where Hemostemix Inc is listed

ListingExchangeCountryCurrency
TSXV:HEM · Home listingTSXVCanadaCAD
OTC:HMTXFOTCUnited StatesUSD
LS Exchange:A2QQGULS ExchangeGermanyEUR
Cboe Canada:HEMCboe CanadaCanadaCAD
Frankfurt:2VF0 · This pageFrankfurtGermanyEUR
Lang & Schwarz:A2QQGULang & SchwarzGermanyEUR
Stuttgart:2VF0StuttgartGermanyEUR
Tradegate:2VF0TradegateGermanyEUR

Valuation

Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$11.03M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P/TSX Composite
0.47

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Hemostemix Inc · TSXV:HEMUS$5.35MUS$7.69Mn/an/an/an/an/an/a0.47
Oncotelic Therapeutics Inc · OTC:OTLCUS$5.58MUS$5.52M0.0×n/an/a0.0×n/a0.0×0.07
Theriva Biologics, Inc. · AMEX:TOVXUS$5.51MUS$461,120n/an/an/a0.5×n/a0.3×2.65
Curative Biotechnology Inc · OTC:CUBTUS$5.34MUS$6.55Mn/an/an/an/an/an/a1.27
Abpro Holdings, Inc. · OTC:ABPOUS$5.31MUS$1.07M2.6×n/an/an/an/an/a-0.79
CNS Pharmaceuticals, Inc. · NASDAQ:CNSPUS$5.25M−US$11.96Mn/an/an/a0.3×n/a0.0×0.74
Soligenix, Inc. · NASDAQ:SNGXUS$5.14M−US$3.61Mn/an/an/a0.8×n/a0.0×1.76
Rakovina Therapeutics Inc · TSXV:RKVUS$5.10MUS$7.20Mn/an/an/an/an/an/a-0.43
StimCell Energetics Inc. · OTC:STMEUS$5.10MUS$5.09Mn/an/an/an/an/an/a0.99
Longeveron Inc. · NASDAQ:LGVNUS$5.05M−US$1.78Mn/a−1.5×n/a1.1×n/a0.1×1.55
Oncodesign Precision Medicine S.A. · EURONEXT:ALOPMUS$5.04MUS$8.61M0.8×30.0×0.9×1.2×n/a1.6×n/a
Median of the othersUS$5.20MUS$3.08M0.8×14.3×0.9×0.7×0.1×0.99

Team and board

Officers

OfficerRole
Thomas A. SmeenkPresident & CEO. Co-Founder
Fraser HendersonChief Medical Officer
Shaune HardingDirector of Patient Care & Clinical Operations

Board

DirectorRole
Peter LaceyChairman of the Board
Desirée CoxDirector
Loran SwanbergDirector
Ronnie HershmanDirector

Events

Next results
Nov 27, 2026 (expected)
QuarterResultsShare move
Q1 2023May 29, 2023 · After close−3.9%
Q3 2022Nov 29, 2022 · After close+6.7%
Q2 2022Aug 30, 2022 · Before open−38.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (2026)Investor deck17 slidesNov 4, 2026
Investor Presentation (2026)Investor deck23 slides2026
Investor Presentation (2025)Investor deck22 slidesNov 3, 2025
Investor Presentation (July 2023)Investor deck23 slidesJul 5, 2023
Investor Presentation (April 2023)Investor deck24 slidesApril 2023
Investor Presentation (November 2022)Investor deck22 slidesNovember 2022
Investor Presentation (March 2022)Investor deck18 slidesMar 29, 2022
Non-Deal Roadshow (February 2022)Roadshow14 slidesFebruary 2022
Investor Presentation (January 2021)Investor deck22 slidesJan 25, 2021
Investor Presentation (April 2019)Investor deck20 slidesApr 1, 2019
All 14 decks
DeckKindSlidesDate
Investor Presentation (July 2018)Investor deck21 slidesJul 26, 2018
Investor Presentation (November 2015)Investor deck21 slidesNov 12, 2015
Investor Presentation (September 2015)Investor deck21 slidesSeptember 2015
Investor Presentation (July 2015)Investor deck19 slidesJuly 2015

Open Decks

Financings

RaiseDateIn US dollars
Private placement of units
Tranche closed: C$380,500 in the latest tranche · C$0.05 a unit · ½ warrant at C$0.12 for 24 months
Use of proceeds: ACP-01 manufacturing, clinical-program preparation, regulatory submissions, physician education and general working capital
Oct 7, 2026
Private placement of units
Tranche closed: C$360,000 raised · C$0.05 a unit · ½ warrant at C$0.12 for 24 months
Insiders: Certain directors of the Company participated, directly and indirectly, in the Offering
Use of proceeds: Sales, marketing, patient acquisition and commercialization; ACP-01 production; Bahamas regulatory fees; working capital
Jun 26, 2026
Private placement of units
Announced: up to C$1M · C$0.05 a unit · ½ warrant at C$0.12 for 24 months
Insiders: Certain directors of the Company may participate in the private placement, a related party transaction under MI 61-101
Use of proceeds: Sales, marketing, patient acquisition, physician education, commercialization, ACP-01 production, Bahamas regulatory fees and working capital
Jun 17, 2026US$712,555
Private placement of common shares
Closed: C$480,000 raised · C$0.12 a share
Use of proceeds: General working capital, including regulatory, clinical and commercialization work on ACP-01 (VesCell)
Dec 31, 2025US$350,212
Private placement of units
Closed: C$518,440 raised · C$0.11 a unit · 1 warrant at C$0.15 for 24 months
Buyers: Director of the Company (participating in the Offering)
Insiders: Certain directors participated directly and indirectly
Use of proceeds: General working capital and ongoing operations, including marketing and sales of VesCell
Dec 2, 2025
Private placement of common shares
Closed: C$280,594 raised · C$0.125 a share
Insiders: The investor is arm's length and not a Related Party to the Company.
Use of proceeds: General working capital, ongoing operating expenses and business development.
Nov 18, 2025US$200,467
Therapy Convertible Debenture
Tranche closed: US$1.14M raised
Use of proceeds: General working capital, corporate overhead and research and development activities
Aug 20, 2025
Private placement of units
Closed: C$2.97M raised · C$0.1 a unit · 1 warrant at C$0.15 for 24 months
Buyers: Peter Lacey (subscribed for $1,500,000); Loran Swanberg (subscribed for $100,000); Mr. Lacey (subscribed to 15,000,000 Units; now owns 24,316,937 Common Shares (13.40% non-diluted))
Insiders: Directors Peter Lacey and Loran Swanberg directly and indirectly participated; related party transaction under MI 61-101
Use of proceeds: Repay CD#1 in full at a 50% discount ($1,250,000) and general working capital, including marketing and sales of VesCell
Jul 31, 2025US$2.18M
Private placement of common shares
Closed: C$469,366 raised · C$0.12 a share
Insiders: The investor is arm's length to the Company and is not a Related Party
Use of proceeds: General working capital, operational expenses and business development
Jul 4, 2025US$345,046
Private placement of common shares
Closed: US$336,500 raised · C$0.295 a share
Buyers: CytoImmune (USD $336,500 for 1,634,466 Common Shares); CytoImmune Therapeutics LLC (1,634,466 Common Shares at CAD $0.295 each)
Use of proceeds: General working capital, including business development activities
May 12, 2025
All 11 raises
RaiseDateIn US dollars
Private placement of units
Closed: C$2.73M raised · C$0.05 a unit · 1 warrant at C$0.12 for 24 months
Insiders: Certain directors of the Company participated in the Offering, a related party transaction under MI 61-101
Use of proceeds: Advance stem cell therapeutics platform, initiate sales and process initial ACP batches, pay fees, and general working capital
Dec 3, 2024

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in CAD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue2234951.10K2.45K1.69K00
Gross profit-223-495-1.10K-2.45K-1.69K00
Research and development2.49M2.97K384.9K622.7K179.9K650.0K2.35M2.26M60.3K828.6K
Selling, general and administrative2.56M1.89M1.33M3.50M5.98M6.81M2.34M4.16M2.75M2.31M
Operating income-5.63M-1.98M-2.16M-4.58M-6.67M-7.47M-4.70M-6.42M-2.81M-3.71M
Depreciation and amortization461002234951.10K2.45K1.69K1.69K745.6K38.6K
EBITDA-5.63M-1.98M-2.16M-4.58M-6.67M-7.47M-4.69M-6.42M-2.06M-3.67M
Interest expense453.2K615.2K550.1K350.3K10.5K106.0K105.0K01.14M2.27K
Income before tax-4.71M-2.62M-2.50M-4.75M-6.54M-7.77M-4.87M-6.18M-3.51M-3.79M
Income tax-3486.9K-255.8K106.0K105.0K6.22K-60.2K-10.3K
Net income-4.71M-2.62M-2.50M-5.24M-6.29M-7.77M-4.87M-6.19M-3.93M-3.78M
Earnings per share, basic-0.02-0.02-0.03-0.07-0.11-0.24-0.32-0.41-0.56-1.12

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents682.1K705.7K155.4K135.7K219.4K258.0K24.1K1.47M3.96M34.8K
Short-term investments59.6K01.25M
Receivables25.1K138.9K342.7K2.06M75.8K191.2K89.1K90.4K
Inventory-343-45.5K-13.3K-88.2K-62.0K-74.4K
Current assets846.9K991.8K313.6K464.9K562.1K2.32M99.8K1.66M5.30M125.3K
Property, plant and equipment4062.00K4.45K101.8K
Goodwill11
Total assets846.9K991.9K313.8K465.3K563.0K2.32M104.3K1.66M5.30M227.1K
Accounts payable1.73M2.77M2.88M2.40K4.37M3.25M2.09M1.17M412.0K953.4K
Current liabilities1.73M2.77M2.88M2.62M4.37M3.42M4.15M1.17M464.8K3.38M
Long-term debt3.60M4.94M4.32M4.13M1.48M312.7K
Total debt4.32M4.13M1.48M175.0K2.06M1.39M
Total liabilities5.82M8.20M7.68M7.23M5.85M3.42M4.15M1.17M464.8K3.69M
Shareholders' equity-4.97M-7.20M-7.37M-6.77M-5.28M-1.10M-4.05M487.8K4.84M-3.46M
Shares outstanding195.3M140.6M82.5M70.0M57.4M32.2M15.0M14.9M6.98M3.37M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-4.53M-1.90M-1.50M-6.10M-3.48M-5.98M-3.40M-2.69M-3.21M-2.69M
Capital spending000000-6.14K-6.14K-6.14K-1.53K
Free cash flow-4.53M-1.90M-1.50M-6.10M-3.48M-5.98M-3.41M-2.69M-3.21M-2.69M
Cash from investing-6.14K-6.14K-6.14K-1.53K
Cash from financing4.66M2.45M1.52M6.02M3.27M6.21M1.96M201.6K7.14M2.22M
Share buybacks5.89M76.0K
Change in cash-23.6K550.3K19.7K-83.7K-38.5K233.9K-1.45M-2.49M3.92M-471.7K

Open Financials

Cap table

Built by 6ix from Hemostemix Inc’s releases · as of Oct 7, 2026

Common shares
219,051,432
Fully diluted
295,732,757

Fully diluted

LineSharesAs of
Common shares219,051,432Oct 7, 2026
Warrants70,401,325Jul 30, 2026
Options and RSUs6,280,000Jul 22, 2026

Warrants and options

Lot
Warrants · C$0.12 · expire about Jul 2028
Warrants · C$0.12 · expire about Jun 2028
Warrants · C$0.15 · expire about Nov 2027
Warrants · C$0.15 · expire about Jul 2027
Warrants · C$0.12 · expire about Nov 2026
Broker warrants · C$0.06 · expiry not stated
Broker warrants · C$0.06 · expiry not stated
Broker warrants · C$0.06 · expiry not stated
Stock options · C$0.06 · expiry not stated

Share count over time

CountShares
Oct 7, 2026219,051,432
Jul 30, 2026211,441,432
Jun 30, 2026204,996,432

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Loran Lavern Swanberg
Director of Issuer
Placement2,000,000CAD 0.05CAD 100KJun 26, 2026
Peter Alan Lacey
Director of Issuer
Placement2,000,000CAD 0.05CAD 100KJun 25, 2026
Loran Lavern Swanberg
Director of Issuer
Buy26,500CAD 0.06CAD 1,458Jun 10, 2026
Loran Lavern Swanberg
Director of Issuer
Buy22,055CAD 0.06CAD 1,323Jun 10, 2026
Loran Lavern Swanberg
Director of Issuer
Buy20,000CAD 0.06CAD 1,200Jun 10, 2026
Loran Lavern Swanberg
Director of Issuer
Sale1,265,000CAD 0.06CAD 69,575May 20, 2026
Loran Lavern Swanberg
Director of Issuer
Buy1,265,000CAD 0.06CAD 69,575May 20, 2026
Loran Lavern Swanberg
Director of Issuer
Sale1,265,000CAD 0.09CAD 114KFeb 9, 2026
Loran Lavern Swanberg
Director of Issuer
Buy1,265,000CAD 0.09CAD 114KFeb 9, 2026
Thomas Smeenk
Director of Issuer
Buy20,000CAD 0.09CAD 1,700Dec 16, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Desiree CoxDirector · Since May 25, 2026
Fraser HendersonChief Medical Officer · Since at least Jan 16, 2026
John M. ViglottiSVP Corporate Services · Sep 18, 2025 – Nov 4, 2026 · Past
Loran SwanbergDirector · Since at least Jul 31, 2025
Peter LaceyChairman of the Board · Since at least Mar 9, 2026
Ronnie HershmanDirector · Since at least Nov 4, 2026
Shaune HardingDirector of Patient Care & Clinical Operations · Since at least Dec 4, 2025
Thomas SmeenkPresident & CEO. Co-Founder · Since at least Oct 7, 2026

Open People

Log in to ask 6ix AI your own questions about Hemostemix Inc.